Last updated: 2026-09-16 12:18:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
GeneDx Holdings Corp. (WGS) operates in the SERVICES-HEALTH SERVICES sector and is listed on NASDAQ. The stock is currently priced at $94,65, with a market capitalisation of $2,68B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $32,21 to $170,87. This page covers its latest market performance, valuation, price trends and company information.
$2,68B | |
$94,77 | |
$170,87 | |
$1,16 | |
$94,64 | |
546,00 | |
729,95K | |
-- | |
$170,87 | |
$32,21 | |
-- | |
-- |
GeneDx Holdings Corp. (WGS) is trading at $94,65 in pre-market trading as of 2026-09-16 12:08:00, up 0,01% ($0,01) from the previous close of $94,64
Pre-market trading shows how investors are pricing WGS before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, GeneDx Holdings Corp. (WGS) moved from $85,99 to $94,65, representing a gain of 10,07% ($8,66).
The stock traded between $82,00 and $97,73 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 517,01 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 45,0%
WGS is currently trading at $94,65, placing it 45,0% of the way from its 52-week low of $32,21 to its 52-week high of $170,87. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
| Industry | SERVICES-HEALTH SERVICES |
| Employees | 1300 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of GeneDx Holdings Corp. (WGS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.